HBC — Hofseth Biocare ASA Share Price
Last trade - 00:00- NOK684.45m
- NOK827.92m
- NOK194.87m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.95 | ||
| Price to Tang. Book | 7.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.79% | ||
| Return on Equity | -94.82% | ||
| Operating Margin | -50.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 67.78 | 69.25 | 87.62 | 120.45 | 194.87 | n/a | n/a | 26.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hofseth Biocare ASA is a Norway-based biotech company that offers ingredients and finished products for humans and animals. The Company’s business is development, manufacturing, marketing and sale of marine ingredients such as oil, calcium and protein products. Its main products are Salmon protein hydrolysate (ProGo), which is a protein for sports, endurance, and recovery powders; Fresh, all-natural salmon oil (OmeGo) that has a full spectrum of omega fatty acids, including EPA, DHA and DPA, totaling 21 different fatty acids; Calcium bone powder (CalGo) is a natural marine collagenic bone powder and CollaGo is a Collagen Peptide powder optimised to improve the beauty of hair, skin and nails. Hofseth BioCare's headquarters are in Aalesund with branches in Oslo, Chicago, Mumbai, Tokyo and Menlo Park, California.
Directors
- Ola Holen CHM (57)
- Roger Hofseth CEO (45)
- Jon Odegard CFO
- Matt Mixter CEX
- Bomi Framroze CSO (56)
- Kai Thuen DMK
- Henriette Godo Heggdal OTH (36)
- Oddvar Myrmo OTH (52)
- Roald Rogne OTH (47)
- Christoph Baldegger IND
- Torill Standal Eliassen IND
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- August 29th, 2009
- Public Since
- December 2nd, 2011
- No. of Shareholders
- 1,475
- No. of Employees
- 65
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 411,081,030
- Address
- Kipervikgata 13, ALESUND, 6003
- Web
- https://hofsethbiocare.com
- Phone
- +47 73102200
- Contact
- James Berger
- Auditors
- Ernst & Young AS
Upcoming Events for HBC
Similar to HBC
Aker Biomarine ASA
Oslo Stock Exchange
Akva ASA
Oslo Stock Exchange
Andfjord Salmon AS
Oslo Stock Exchange
Arctic Fish Holding AS
Oslo Stock Exchange
Atlantic Sapphire ASA
Oslo Stock Exchange
FAQ
As of Today at 21:08 UTC, shares in Hofseth Biocare ASA are trading at NOK1.67. This share price information is delayed by 15 minutes.
Shares in Hofseth Biocare ASA last closed at NOK1.67 and the price had moved by -41.04% over the past 365 days. In terms of relative price strength the Hofseth Biocare ASA share price has underperformed the FTSE Global All Cap Index by -49.14% over the past year.
There is no consensus recommendation for this security.
Find out moreHofseth Biocare ASA does not currently pay a dividend.
Hofseth Biocare ASA does not currently pay a dividend.
Hofseth Biocare ASA does not currently pay a dividend.
To buy shares in Hofseth Biocare ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK1.67, shares in Hofseth Biocare ASA had a market capitalisation of NOK684.45m.
Here are the trading details for Hofseth Biocare ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: HBC
Based on an overall assessment of its quality, value and momentum Hofseth Biocare ASA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hofseth Biocare ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -24.78%.
As of the last closing price of NOK1.67, shares in Hofseth Biocare ASA were trading -23.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hofseth Biocare ASA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK1.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hofseth Biocare ASA's management team is headed by:
- Ola Holen - CHM
- Roger Hofseth - CEO
- Jon Odegard - CFO
- Matt Mixter - CEX
- Bomi Framroze - CSO
- Kai Thuen - DMK
- Henriette Godo Heggdal - OTH
- Oddvar Myrmo - OTH
- Roald Rogne - OTH
- Christoph Baldegger - IND
- Torill Standal Eliassen - IND